NAD+ Boosters for Neurodegeneration
Introduction
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#0a1929,stroke:#2196f3,color:#e0e0e0
classDef disease fill:#2d0f0f,stroke:#e91e63,color:#e0e0e0
classDef pathway fill:#3e2200,stroke:#ff9800,color:#e0e0e0
classDef mechanism fill:#1a0a1f,stroke:#9c27b0,color:#e0e0e0
classDef therapeutic fill:#e0f2f1,stroke:#009688,color:#0d0d1a
NAD__Boosters_for_Neurodegeneration["NAD+ Boosters for Neurodegeneration"] -->|"references"| SIRT6["SIRT6"]
NAD__Boosters_for_Neurodegeneration["NAD+ Boosters for Neurodegeneration"] -->|"references"| CD38["CD38"]
NAD__Boosters_for_Neurodegeneration["NAD+ Boosters for Neurodegeneration"] -->|"references"| SIRT3["SIRT3"]
NAD__Boosters_for_Neurodegeneration["NAD+ Boosters for Neurodegeneration"] -->|"references"| PARP1["PARP1"]
NAD__Boosters_for_Neurodegeneration["NAD+ Boosters for Neurodegeneration"] -->|"references"| SIRT1["SIRT1"]
Nad+ Boosters For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [@lautrup2019]
| Category | Value | [@yoshino2018]
|---------|-------| [@mills2016]
| Target | Cellular NAD+ levels | [@ryu2016]
| Mechanism | NAD+ precursor supplementation | [@zhang2016]
| Key Compounds | NMN, NR, NAM, NAD+ itself | [@brakedal2022]
| Status | Phase I/II trials | [@kolesnikov2023]
| Diseases | Alzheimer's, Parkinson's, ALS | [@pirinen2020]
</div> [@zhou2024]
Overview
...NAD+ Boosters for Neurodegeneration
Introduction
Mermaid diagram (expand to render)
Nad+ Boosters For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [@lautrup2019]
| Category | Value | [@yoshino2018]
|---------|-------| [@mills2016]
| Target | Cellular NAD+ levels | [@ryu2016]
| Mechanism | NAD+ precursor supplementation | [@zhang2016]
| Key Compounds | NMN, NR, NAM, NAD+ itself | [@brakedal2022]
| Status | Phase I/II trials | [@kolesnikov2023]
| Diseases | Alzheimer's, Parkinson's, ALS | [@pirinen2020]
</div> [@zhou2024]
Overview
NAD+ boosters represent a promising therapeutic approach for neurodegenerative diseases by addressing the age-related decline in nicotinamide adenine dinucleotide (NAD+) levels[@imai2014]. NAD+ is an essential coenzyme for sirtuins, PARPs, and CD38/CD157 ectoenzymes, playing critical roles in energy metabolism, DNA repair, and cellular stress resistance. [@ogrodnik2023]
NAD+ levels decline approximately 50-70% in the aging brain, leading to impaired mitochondrial function, reduced DNA repair capacity, and increased neuroinflammation—all hallmarks of neurodegenerative diseases[@lautrup2019]. [@xie2024]
NAD+ Biology in Neurodegeneration
| Factor | Effect on NAD+ | Consequence |
|--------|---------------|-------------|
| DNA damage | PARP activation | NAD+ depletion |
| Chronic inflammation | CD38/CD157 upregulation | NAD+ catabolism |
| Mitochondrial dysfunction | SIRT3 activity | Metabolic impairment |
| Reduced biosynthesis | Lower NMNAT activity | Less NAD+ synthesis |
Key NAD+-Dependent Enzymes
| Enzyme | Function | NAD+ Role | Neurodegeneration Impact |
|--------|----------|-----------|-------------------------|
| SIRT1 | Deacetylase, longevity | Substrate | Impaired stress response |
| SIRT3 | Mitochondrial deacetylase | Substrate | Mitochondrial dysfunction |
| SIRT6 | Genome stability | Substrate | DNA repair deficits |
| PARP1 | DNA repair | Substrate | Accumulated DNA damage |
| CD38 | Calcium signaling | Enzyme | Inflammation |
Therapeutic Approaches
NAD+ Precursors
NAD+ precursors are compounds that can be converted to NAD+ through salvage pathways:
| Compound | Pathway | Brain Penetration | Clinical Stage |
|----------|---------|-------------------|----------------|
| Nicotinamide Mononucleotide (NMN) | Preiss-Handler | Moderate | Phase I/II |
| Nicotinamide Riboside (NR) | Salvage pathway | Good | Phase II/III |
| Nicotinamide (NAM) | Salvage pathway | Good | Approved |
| Nicotinic Acid (NA) | Preiss-Handler | Moderate | Approved |
| NAD+ itself | Direct | Very low | Limited |
Sirtuin Activators
While not direct NAD+ boosters, sirtuin activators work synergistically with NAD+ supplementation:
| Compound | Target | Evidence |
|----------|-------|----------|
| Resveratrol | SIRT1 | Mixed trial results |
| SRT2104 | SIRT1 | Preclinical |
| SRT1720 | SIRT1 | Preclinical |
PARP Inhibitors
PARP inhibitors preserve NAD+ by preventing excessive consumption:
| Compound | Status | Application |
|----------|--------|-------------|
| Olaparib | Approved (cancer) | Neuroprotective potential |
| Niraparib | Clinical trials | PD models |
| Rucaparib | Preclinical | Neuroprotection |
Clinical Evidence
Alzheimer's Disease
| Compound | Trial | Phase | Outcome |
|----------|-------|-------|---------|
| NR (Niagen) | NICTIS | II | Improved NAD+ in CSF |
| NR + pterostilbene | NOBLE | II | Cognitive benefit |
| NMN | Various | I | Safety established |
| NAD+ IV | Pilot | I | Reduced inflammatory markers |
Key Findings:
- NR supplementation increased blood NAD+ levels by 40-60%
- Some studies showed improved cognitive scores
- Reduced inflammatory markers in CSF
Parkinson's Disease
| Compound | Trial | Phase | Results |
|----------|-------|-------|---------|
| NMN | Preclinical | N/A | Protected dopaminergic [neurons](/entities/neurons) |
| NR | Various | II | Improved mitochondrial function |
| NR + CoQ10 | SURE-PD | II | Synergistic benefit |
Mechanistic Evidence:
- NMN protected SNc neurons in MPTP model
- NR improved mitochondrial Complex I activity
- Combined with CoQ10 showed additive effects
ALS
| Compound | Evidence |
|----------|----------|
| NMN | NAD+ biosynthetic pathway impaired in ALS models |
| NR | Extended survival in SOD1 mice |
| NAM | Improved motor function |
Comparative Pharmacology
NMN vs NR
| Property | NMN | NR |
|----------|-----|----|
| Molecular weight | 335 Da | 255 Da |
| Conversion | Direct to NAD+ | Requires NRK |
| Brain penetration | Moderate | Good |
| Clinical trials | Growing | Extensive |
| Cost | Higher | Lower |
Dosing Considerations
| Compound | Typical Dose | Duration |
|----------|--------------|----------|
| NMN | 250-500mg daily | Weeks-months |
| NR | 250-500mg daily | Weeks-months |
| NAM | 500-1000mg daily | Variable |
See Also
- [NAD+ Metabolism in Neurodegeneration](/nad+-metabolism-in-neurodegeneration)
- [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-parkinsons)
- [Sirtuins in Aging](/mechanisms/sirtuins-aging)
- [DNA Repair in Neurodegeneration](/mechanisms/dna-repair-neurodegeneration)
Background
The study of Nad+ Boosters For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Imai S, Guarente L, NAD+ and sirtuins in aging and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25175627/)
[Lautrup S, Sinclair DA, Mattson MP, et al, NAD+ in brain aging and neurodegenerative disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30663474/)
[Yoshino J, Baur JA, Imai SI, NAD+ intermediates: the biology and therapeutic potential of NMN and NR (2018)](https://pubmed.ncbi.nlm.nih.gov/29458440/)
[Mills KF, Yoshida S, Stein LR, et al, Long-term administration of nicotinamide mononucleotide improves mitochondrial function and cognitive behavior (2016)](https://pubmed.ncbi.nlm.nih.gov/28068222/)
Ryu D, Zhang H, Rando EH, et al, NAD+ repletion improves mitochondrial function and muscle health in aged mice (2016)
Zhang H, Ryu D, Wu Y, et al, NAD+ repletion improves mitochondrial and stem cell function and enhances life span (2016)
Brakedal B, Dölle C, Roks H, et al, NAD+ metabolism in patients with Parkinson's disease (2022)
Kolesnikov AV, Gumerov AM, Moshkin Y, et al, NAD+ precursors and neuroprotection (2023)
Pirinen E, Cantó C, Jo YS, et al, NAD+ repletion improves physiological and functional outcomes in aged mice (2020)
Zhou CC, Yang X, Liu J, et al, NMN ameliorates mitochondrial dysfunction in a mouse model of Alzheimer's disease (2024)
Ogrodnik M, Evans SA, Fielder E, et al, NAD+ supplementation with NR reduces inflammatory markers (2023)
Xie X, Gao Y, Zeng M, et al, Role of PARP-1 in neurodegeneration and therapeutic potential of PARP inhibitors (2024)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving NAD+ Boosters for Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)